The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We c...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2014/715908 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387203480780800 |
|---|---|
| author | Se Hwa Kim Soo Young Yoon Sung-Kil Lim Yumie Rhee |
| author_facet | Se Hwa Kim Soo Young Yoon Sung-Kil Lim Yumie Rhee |
| author_sort | Se Hwa Kim |
| collection | DOAJ |
| description | Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We conducted a cross-sectional observational study of 302 type 2 diabetic patients with or without chronic kidney disease. Serum sclerostin level was analyzed by ELISA, and renal function was assessed by estimated glomerular filtration rate (eGFR) using chronic kidney disease epidemiology collaboration (CKD-EPI) equation. Results. There was a strong correlation between sclerostin level with renal function presented as serum creatinine (r=0.745, P<0.001) and eGFR (r=-0.590, P<0.001). Serum sclerostin level was significantly higher in patients with CKD-G3 stage than those with CKD-G1/2 stages after adjusting for age, sex, and BMI (P=0.011). Patients with CKD-G4/5 stages had dramatically increased level of circulating sclerostin. Multiple regression analyses found that age, sex, and eGFR were independent determining factors for circulating sclerostin level. Conclusion. Our data showed that serum sclerostin levels start to increase in diabetic patients with CKD-G3 stage. Further studies are needed to establish the potential role of elevated sclerostin in diabetic patients with CKD. |
| format | Article |
| id | doaj-art-2c024ab6a2a743e694bc3ee38b21db85 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-2c024ab6a2a743e694bc3ee38b21db852025-08-20T03:55:17ZengWileyInternational Journal of Endocrinology1687-83371687-83452014-01-01201410.1155/2014/715908715908The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 DiabetesSe Hwa Kim0Soo Young Yoon1Sung-Kil Lim2Yumie Rhee3Division of Endocrinology, Department of Internal Medicine, Kwandong University College of Medicine, 100-25 Simgok-ro, Seo-gu, Incheon 404-834, Republic of KoreaDivision of Nephrology, Department of Internal Medicine, Kwandong University College of Medicine, 100-25 Simgok-ro, Seo-gu, Incheon 404-834, Republic of KoreaDepartment of Internal Medicine, Severance Hospital, Endocrine Research Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of KoreaDepartment of Internal Medicine, Severance Hospital, Endocrine Research Institute, Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Republic of KoreaObjective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We conducted a cross-sectional observational study of 302 type 2 diabetic patients with or without chronic kidney disease. Serum sclerostin level was analyzed by ELISA, and renal function was assessed by estimated glomerular filtration rate (eGFR) using chronic kidney disease epidemiology collaboration (CKD-EPI) equation. Results. There was a strong correlation between sclerostin level with renal function presented as serum creatinine (r=0.745, P<0.001) and eGFR (r=-0.590, P<0.001). Serum sclerostin level was significantly higher in patients with CKD-G3 stage than those with CKD-G1/2 stages after adjusting for age, sex, and BMI (P=0.011). Patients with CKD-G4/5 stages had dramatically increased level of circulating sclerostin. Multiple regression analyses found that age, sex, and eGFR were independent determining factors for circulating sclerostin level. Conclusion. Our data showed that serum sclerostin levels start to increase in diabetic patients with CKD-G3 stage. Further studies are needed to establish the potential role of elevated sclerostin in diabetic patients with CKD.http://dx.doi.org/10.1155/2014/715908 |
| spellingShingle | Se Hwa Kim Soo Young Yoon Sung-Kil Lim Yumie Rhee The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes International Journal of Endocrinology |
| title | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
| title_full | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
| title_fullStr | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
| title_full_unstemmed | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
| title_short | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
| title_sort | effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes |
| url | http://dx.doi.org/10.1155/2014/715908 |
| work_keys_str_mv | AT sehwakim theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT sooyoungyoon theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT sungkillim theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT yumierhee theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT sehwakim effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT sooyoungyoon effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT sungkillim effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT yumierhee effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes |